Erratum: Use of a Lipid-Coated Mesoporous Silica Nanoparticle Platform for Synergistic Gemcitabine and Paclitaxel Delivery to Human Pancreatic Cancer in Mice (ACS Nano (2015) 9:4 (3540-3557) DOI: 10.1021/acsnano.5b00510);Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gmcitabine and pclitaxel dlivery to hman pncreatic cncer in mice

ACS Nano

Volumn 9, Issue 4, 2015, Pages 3540-3557

  Meng, Huan ^a   Wang, Meiying ^a   Liu, Huiyu ^a,c   Liu, Xiangsheng ^a   Situ, Allen ^a   Wu, Bobby ^a   Ji, Zhaoxia ^a   Chang, Chong Hyun ^a   Nel, Andre E ^a,b  

^a Division of NanoMedicine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

co delivery; gemcitabine; mesoporous silica nanoparticle; paclitaxel; pancreatic cancer; ratiometric; synergy

Indexed keywords

BIOMOLECULES; CONTROLLED DRUG DELIVERY; DISEASES; DRUG DOSAGE; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPID BILAYERS; MAMMALS; MESOPOROUS MATERIALS; METABOLITES; SHRINKAGE; SILICA NANOPARTICLES; TUMORS;

CO DELIVERIES; GEMCITABINE; MESOPOROUS SILICA NANOPARTICLES; PACLITAXEL; PANCREATIC CANCERS; RATIOMETRIC; SYNERGY;

TARGETED DRUG DELIVERY;

130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DRUG CARRIER; GEMCITABINE; LIPID BILAYER; NANOPARTICLE; PACLITAXEL; SILICON DIOXIDE;

ANALOGS AND DERIVATIVES; ANIMAL; CELL TRANSFORMATION; CHEMISTRY; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; LIPID BILAYER; METABOLISM; MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; POROSITY; TUMOR CELL LINE;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DRUG CARRIERS; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPID BILAYERS; MICE; NANOPARTICLES; PACLITAXEL; PANCREATIC NEOPLASMS; POROSITY; SILICON DIOXIDE;

EID: 84928939851     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.6b03110     Document Type: Erratum

References (63)

1. Cancer Facts & Figures; American Cancer Society, 2014; http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf.
2. Mini, E.; Nobili, S.; Caciagli, B.; Landini, I.; Mazzei, T. Cellular Pharmacology of Gemcitabine Ann. Oncol. 2006, 17, v7-v12
3. Erkan, M.; Hausmann, S.; Michalski, C. W.; Fingerle, A. A.; Dobritz, M.; Kleeff, J.; Friess, H. The Role of Stroma in Pancreatic Cancer: Diagnostic and Therapeutic Implications Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 454-467
4. Jacobetz, M. A.; Chan, D. S.; Neesse, A.; Bapiro, T. E.; Cook, N.; Frese, K. K.; Feig, C.; Nakagawa, T.; Caldwell, M. E.; Zecchini, H. I. Hyaluronan Impairs Vascular Function and Drug Delivery in a Mouse Model of Pancreatic Cancer Gut 2012, 62, 112-120
5. Von Hoff, D. D.; Ervin, T.; Arena, F. P.; Chiorean, E. G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S. A.; Ma, W. W.; Saleh, M. N. Increased Survival in Pancreatic Cancer with Nab-Paclitaxel Plus Gemcitabine N. Engl. J. Med. 2013, 369, 1691-1703
6. Frese, K. K.; Neesse, A.; Cook, N.; Bapiro, T. E.; Lolkema, M. P.; Jodrell, D. I.; Tuveson, D. A. Nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer Cancer Discovery 2012, 2, 260-269
7. Awasthi, N.; Zhang, C.; Schwarz, A. M.; Hinz, S.; Wang, C.; Williams, N. S.; Schwarz, M. A.; Schwarz, R. E. Comparative Benefits of Nab-Paclitaxel over Gemcitabine or Polysorbate-Based Docetaxel in Experimental Pancreatic Cancer Carcinogenesis 2013, 34, 2361-2369
8. Bourzac, K. Nanotechnology: Carrying Drugs Nature 2012, 491, S58-S60
9. Federico, C.; Morittu, V.; Britti, D.; Trapasso, E.; Cosco, D. Gemcitabine-Loaded Liposomes: Rationale, Potentialities and Future Perspectives Int. J. Nanomed. 2012, 2012, 5423-5436
10. Mai, W. X.; Meng, H. Mesoporous Silica Nanoparticles: A Multifunctional Nano Therapeutic System Integr. Biol. 2013, 5, 19-28
11. Meng, H.; Liong, M.; Xia, T.; Li, Z.; Ji, Z.; Zink, J. I.; Nel, A. E. Engineered Design of Mesoporous Silica Nanoparticles To Deliver Doxorubicin and P-Glycoprotein siRNA To Overcome Drug Resistance in a Cancer Cell Line ACS Nano 2010, 4, 4539-4550
12. Meng, H.; Mai, W. X.; Zhang, H.; Xue, M.; Xia, T.; Lin, S.; Wang, X.; Zhao, Y.; Ji, Z.; Zink, J. I. Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles To Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo ACS Nano 2013, 7, 994-1005
13. Meng, H.; Xue, M.; Xia, T.; Ji, Z.; Tarn, D. Y.; Zink, J. I.; Nel, A. E. Use of Size and a Copolymer Design Feature To Improve the Biodistribution and the Enhanced Permeability and Retention Effect of Doxorubicin-Loaded Mesoporous Silica Nanoparticles in a Murine Xenograft Tumor Model ACS Nano 2011, 5, 4131-4144
14. Meng, H.; Xue, M.; Xia, T.; Zhao, Y.-L.; Tamanoi, F.; Stoddart, J. F.; Zink, J. I.; Nel, A. E. Autonomous In Vitro Anticancer Drug Release from Mesoporous Silica Nanoparticles by pH-Sensitive Nanovalves J. Am. Chem. Soc. 2010, 132, 12690-12697
15. Meng, H.; Xue, M.; Zink, J. I.; Nel, A. E. Development of Pharmaceutically Adapted Mesoporous Silica Nanoparticles Platform J. Phys. Chem. Lett. 2012, 3, 358-359
16. Meng, H.; Yang, S.; Li, Z.; Xia, T.; Chen, J.; Ji, Z.; Zhang, H.; Wang, X.; Lin, S.; Huang, C. Aspect Ratio Determines the Quantity of Mesoporous Silica Nanoparticle Uptake by a Small GTPase-Dependent Macropinocytosis Mechanism ACS Nano 2011, 5, 4434-4447
17. Meng, H.; Zhao, Y.; Dong, J.; Xue, M.; Lin, Y.-S.; Ji, Z.; Mai, W. X.; Zhang, H.; Chang, C. H.; Brinker, C. J. Two-Wave Nanotherapy To Target the Stroma and Optimize Gemcitabine Delivery to a Human Pancreatic Cancer Model in Mice ACS Nano 2013, 7, 10048-10065
18. Sackmann, E. Supported Membranes: Scientific and Practical Applications Science 1996, 271, 43-48
19. Linseisen, F. M.; Hetzer, M.; Brumm, T.; Bayerl, T. Differences in the Physical Properties of Lipid Monolayers and Bilayers on a Spherical Solid Support Biophys. J. 1997, 72, 1659-1667
20. Cauda, V.; Engelke, H.; Sauer, A.; Arcizet, D.; Bräuchle, C.; Rädler, J.; Bein, T. Colchicine-Loaded Lipid Bilayer-Coated 50 nm Mesoporous Nanoparticles Efficiently Induce Microtubule Depolymerization upon Cell Uptake Nano Lett. 2010, 10, 2484-2492
21. Ashley, C. E.; Carnes, E. C.; Epler, K. E.; Padilla, D. P.; Phillips, G. K.; Castillo, R. E.; Wilkinson, D. C.; Wilkinson, B. S.; Burgard, C. A.; Kalinich, R. M. Delivery of Small Interfering RNA by Peptide-Targeted Mesoporous Silica Nanoparticle-Supported Lipid Bilayers ACS Nano 2012, 6, 2174-2188
22. Argyo, C.; Weiss, V.; Bräuchle, C.; Bein, T. Multifunctional Mesoporous Silica Nanoparticles as a Universal Platform for Drug Delivery Chem. Mater. 2013, 26, 435-451
23. Yang, Y.; Song, W.; Wang, A.; Zhu, P.; Fei, J.; Li, J. Lipid Coated Mesoporous Silica Nanoparticles as Photosensitive Drug Carriers Phys. Chem. Chem. Phys. 2010, 12, 4418-4422
24. Mackowiak, S. A.; Schmidt, A.; Weiss, V.; Argyo, C.; von Schirnding, C.; Bein, T.; Bräuchle, C. Targeted Drug Delivery in Cancer Cells with Red-Light Photoactivated Mesoporous Silica Nanoparticles Nano Lett. 2013, 13, 2576-2583
25. van Schooneveld, M. M.; Vucic, E.; Koole, R.; Zhou, Y.; Stocks, J.; Cormode, D. P.; Tang, C. Y.; Gordon, R. E.; Nicolay, K.; Meijerink, A. Improved Biocompatibility and Pharmacokinetics of Silica Nanoparticles by Means of a Lipid Coating: A Multimodality Investigation Nano Lett. 2008, 8, 2517-2525
26. Ashley, C. E.; Carnes, E. C.; Phillips, G. K.; Padilla, D.; Durfee, P. N.; Brown, P. A.; Hanna, T. N.; Liu, J.; Phillips, B.; Carter, M. B. The Targeted Delivery of Multicomponent Cargos to Cancer Cells by Nanoporous Particle-Supported Lipid Bilayers Nat. Mater. 2011, 10, 476-476
27. Liu, J.; Stace-Naughton, A.; Jiang, X.; Brinker, C. J. Porous Nanoparticle Supported Lipid Bilayers (Protocells) as Delivery Vehicles J. Am. Chem. Soc. 2009, 131, 1354-1355
28. Liu, J.; Jiang, X.; Ashley, C.; Brinker, C. J. Electrostatically Mediated Liposome Fusion and Lipid Exchange with a Nanoparticle-Supported Bilayer for Control of Surface Charge, Drug Containment, and Delivery J. Am. Chem. Soc. 2009, 131, 7567-7569
29. Mayer, L.; Janoff, A. Optimizing Combination Chemotherapy by Controlling Drug Ratios Mol. Interventions 2007, 7, 216-223
30. Baker, J. A. R.; Wickremsinhe, E. R.; Li, C. H.; Oluyedun, O. A.; Dantzig, A. H.; Hall, S. D.; Qian, Y.-w.; Ring, B. J.; Wrighton, S. A.; Guo, Y. Pharmacogenomics of Gemcitabine Metabolism: Functional Analysis of Genetic Variants in Cytidine Deaminase and Deoxycytidine Kinase Drug Metab. Dispos. 2013, 41, 541-545
31. Lin, N.; Zeng, S.; Ma, S.; Fan, Y.; Zhong, H.; Fang, L. Determination of Gemcitabine and Its Metabolite in Human Plasma Using High-Pressure Liquid Chromatography Coupled with a Diode Array Detector Acta. Pharmacol. Sin. 2004, 12, 1584-1589
32. Ferrari, M. Cancer Nanotechnology: Opportunities and Challenges Nat. Rev. Cancer 2005, 5, 161-171
33. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an Emerging Platform for Cancer Therapy Nat. Nanotechnol. 2007, 2, 751-760
34. Zhao, F.; Meng, H.; Yan, L.; Wang, B.; Zhao, Y. Nanosurface Chemistry and Dose Govern the Bioaccumulation and Toxicity of Carbon Nanotubes, Metal Nanomaterials and Quantum Dots in Vivo Sci. Bull. 2015, 60, 3-20
35. Hu, C.; Aryal, S.; Zhang, L. Nanoparticle-Assisted Combination Therapies for Effective Cancer Treatment Ther. Delivery 2010, 1, 323-334
36. Parhi, P.; Mohanty, C.; Sahoo, S. K. Nanotechnology-Based Combinational Drug Delivery: An Emerging Approach for Cancer Therapy Drug Discovery Today 2012, 17, 1044-1052
37. Ma, L.; Kohli, M.; Smith, A. Nanoparticles for Combination Drug Therapy ACS Nano 2013, 7, 9518-9525
38. Lammers, T.; Storm, G.; Kiessling, F. Nanomedicine Formulations for Combination Therapies Nano Rev. 2010, 10.3402/nano.v1i0.5705
39. Aryal, S.; Hu, C.-M. J.; Zhang, L. Combinatorial Drug Conjugation Enables Nanoparticle Dual-Drug Delivery Small 2010, 6, 1442-1448
40. Tardi, P.; Johnstone, S.; Harasym, N.; Xie, S.; Harasym, T.; Zisman, N.; Harvie, P.; Bermudes, D.; Mayer, L. In Vivo Maintenance of Synergistic Cytarabine: Daunorubicin Ratios Greatly Enhances Therapeutic Efficacy Leuk. Res. 2009, 33, 129-139
41. Batist, G.; Gelmon, K. A.; Chi, K. N.; Miller, W. H.; Chia, S. K. L.; Mayer, L. D.; Swenson, C. E.; Janoff, A. S.; Louie, A. C. Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors Clin. Cancer Res. 2009, 15, 692-700
42. Aryal, S.; Hu, C.-M. J.; Zhang, L. Polymeric Nanoparticles with Precise Ratiometric Control over Drug Loading for Combination Therapy Mol. Pharmaceutics 2011, 8, 1401-1407
43. Miao, L.; Guo, S.; Zhang, J.; Kim, W. Y.; Huang, L. Nanoparticles with Precise Ratiometric Co-loading and Co-delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer Adv. Funct. Mater. 2014, 24, 6601-6611
44. Von Hoff, D. D.; Ramanathan, R. K.; Borad, M. J.; Laheru, D. A.; Smith, L. S.; Wood, T. E.; Korn, R. L.; Desai, N.; Trieu, V.; Iglesias, J. L. Gemcitabine Plus Nab-Paclitaxel Is an Active Regimen in Patients with Advanced Pancreatic Cancer: A Phase I/II Trial J. Clin. Oncol. 2011, 29, 4548-4554
45. Meng, H.; Xia, T.; George, S.; Nel, A. E. A Predictive Toxicological Paradigm for the Safety Assessment of Nanomaterials ACS Nano 2009, 3, 1620-1627
46. Nel, A.; Xia, T.; Mädler, L.; Li, N. Toxic Potential of Materials at the Nanolevel Science 2006, 311, 622-627
47. Sackmann, E.; Tanaka, M. Supported Membranes on Soft Polymer Cushions: Fabrication, Characterization and Applications Trends Biotechnol. 2000, 18, 58-64
48. 2 H-Nuclear Magnetic Resonance Biophys. J. 1990, 58, 357-362
49. Linseisen, F. M.; Hetzer, M.; Brumm, T.; Bayerl, T. M. Differences in the Physical Properties of Lipid Monolayers and Bilayers on a Spherical Solid Support Biophys. J. 1997, 72, 1659-1667
50. Mornet, S.; Lambert, O.; Duguet, E.; Brisson, A. The Formation of Supported Lipid Bilayers on Silica Nanoparticles Revealed by Cryoelectron Microscopy Nano Lett. 2005, 5, 281-285
51. Roggers, R. A.; Lin, V. S. Y.; Trewyn, B. G. Chemically Reducible Lipid Bilayer Coated Mesoporous Silica Nanoparticles Demonstrating Controlled Release and HeLa and Normal Mouse Liver Cell Biocompatibility and Cellular Internalization Mol. Pharmaceutics 2012, 9, 2770-2777
52. Dengler, E. C.; Liu, J.; Kerwin, A.; Torres, S.; Olcott, C. M.; Bowman, B. N.; Armijo, L.; Gentry, K.; Wilkerson, J.; Wallace, J. Mesoporous Silica-Supported Lipid Bilayers (Protocells) for DNA Cargo Delivery to the Spinal Cord J. Controlled Release 2013, 168, 209-224
53. Sommerwerk, A.; Brüßler, J.; Schäfer, J.; Baginski, L.; Bandulik, M.; Bakowsky, U. Lipid Coated Chitosan Microparticles as Protein Carriers Pulm. Pharmacol. Ther. 2011, 8, 1978-1984
54. Ji, T.; Zhao, Y.; Ding, Y.; Nie, G. Using Functional Nanomaterials To Target and Regulate the Tumor Microenvironment: Diagnostic and Therapeutic Applications Adv. Mater. 2013, 25, 3508-3525
55. Shipley, L. A.; Brown, T. J.; Cornpropst, J. D.; Hamilton, M.; Daniels, W. D.; Culp, H. W. Metabolism and Disposition of Gemcitabine, and Oncolytic Deoxycytidine Analog, in Mice, Rats, and Dogs Drug Metab. Dispos. 1992, 20, 849-855
56. Shu, C. J.; Campbell, D. O.; Lee, J. T.; Tran, A. Q.; Wengrod, J. C.; Witte, O. N.; Phelps, M. E.; Satyamurthy, N.; Czernin, J.; Radu, C. G. Novel PET Probes Specific for Deoxycytidine Kinase J. Nucl. Med. 2010, 51, 1092-1098
57. Moore, M. J.; Goldstein, D.; Hamm, J.; Figer, A.; Hecht, J. R.; Gallinger, S.; Au, H. J.; Murawa, P.; Walde, D.; Wolff, R. A. Erlotinib Plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol. 2007, 25, 1960-1966
58. Zhang, C.; Cai, T.-y.; Zhu, H.; Yang, L.-q.; Jiang, H.; Dong, X.-w.; Hu, Y.-z.; Lin, N.-m.; He, Q.-j.; Yang, B. Synergistic Antitumor Activity of Gemcitabine and ABT-737 in Vitro and in Vivo through Disrupting the Interaction of USP9X and Mcl-1 Mol. Cancer Ther. 2011, 10, 1264-1275
59. Zhang, H.; Ji, Z.; Xia, T.; Meng, H.; Low-Kam, C.; Liu, R.; Pokhrel, S.; Lin, S.; Wang, X.; Liao, Y.-P. Use of Metal Oxide Nanoparticle Band Gap To Develop a Predictive Paradigm for Oxidative Stress and Acute Pulmonary Inflammation ACS Nano 2012, 6, 4349-4368
60. DaCosta, M. V.; Doughan, S.; Han, Y.; Krull, U. J. Lanthanide Upconversion Nanoparticles and Applications in Bioassays and Bioimaging: A Review Anal. Chim. Acta 2014, 832, 1-33
61. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Greenwald, D. R.; Ruoslahti, E. Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs Science 2010, 328, 1031-1035
62. von Maltzahn, G.; Park, J.-H.; Lin, K. Y.; Singh, N.; Schwppe, C.; Mesters, R.; Berdel, W. E.; Ruoslahti, E.; Sailor, M. J.; Bhatia, S. N. Nanoparticles That Communicate in Vivo To Amplify Tumour Targeting Nat. Mater. 2011, 10, 545-552
63. Meng, H.; Xing, G.; Sun, B.; Zhao, F.; Lei, H.; Li, W.; Song, Y.; Chen, Z.; Yuan, H.; Wang, X. Potent Angiogenesis Inhibition by the Particulate Form of Fullerene Derivatives ACS Nano 2010, 4, 2773-2783